Journal
CARDIOVASCULAR TOXICOLOGY
Volume 7, Issue 2, Pages 72-74Publisher
HUMANA PRESS INC
DOI: 10.1007/s12012-007-0014-4
Keywords
myocet; pegylated liposomal doxorubicin; trastuzumab; cardiotoxicity
Categories
Ask authors/readers for more resources
Anthracyclines remain amongst the most active therapeutic agents for breast cancer treatment. Rather than being supplanted by novel targeted agents, they are being combined with them in various schedules. Furthermore, anthracyclines themselves are still being studied, with increasing biological understanding of their biological activity and molecular targets. A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to provide this opportunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available